KR102502087B1 - 혈액 샘플 내의 순환 종양 세포의 디지털 분석 - Google Patents

혈액 샘플 내의 순환 종양 세포의 디지털 분석 Download PDF

Info

Publication number
KR102502087B1
KR102502087B1 KR1020177030104A KR20177030104A KR102502087B1 KR 102502087 B1 KR102502087 B1 KR 102502087B1 KR 1020177030104 A KR1020177030104 A KR 1020177030104A KR 20177030104 A KR20177030104 A KR 20177030104A KR 102502087 B1 KR102502087 B1 KR 102502087B1
Authority
KR
South Korea
Prior art keywords
primer
seq
artificial sequence
cancer
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177030104A
Other languages
English (en)
Korean (ko)
Other versions
KR20170131516A (ko
Inventor
다이엘 에이. 하버
라비 카푸
메메트 토너
샤이아말라 마헤스와란
신 홍
데이빗 도모아끼 미야모토
타냐 토도로바
사라 자바이드
Original Assignee
더 제너럴 하스피탈 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 더 제너럴 하스피탈 코포레이션 filed Critical 더 제너럴 하스피탈 코포레이션
Publication of KR20170131516A publication Critical patent/KR20170131516A/ko
Application granted granted Critical
Publication of KR102502087B1 publication Critical patent/KR102502087B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6851—Quantitative amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/686—Polymerase chain reaction [PCR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/107—Nucleic acid detection characterized by the use of physical, structural and functional properties fluorescence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2563/00—Nucleic acid detection characterized by the use of physical, structural and functional properties
    • C12Q2563/159—Microreactors, e.g. emulsion PCR or sequencing, droplet PCR, microcapsules, i.e. non-liquid containers with a range of different permeability's for different reaction components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2565/00—Nucleic acid analysis characterised by mode or means of detection
    • C12Q2565/60—Detection means characterised by use of a special device
    • C12Q2565/629—Detection means characterised by use of a special device being a microfluidic device
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
KR1020177030104A 2015-03-25 2016-03-25 혈액 샘플 내의 순환 종양 세포의 디지털 분석 Active KR102502087B1 (ko)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201562137891P 2015-03-25 2015-03-25
US62/137,891 2015-03-25
US201562219339P 2015-09-16 2015-09-16
US62/219,339 2015-09-16
US201562253619P 2015-11-10 2015-11-10
US62/253,619 2015-11-10
PCT/US2016/024367 WO2016154600A1 (en) 2015-03-25 2016-03-25 Digital analysis of circulating tumor cells in blood samples

Publications (2)

Publication Number Publication Date
KR20170131516A KR20170131516A (ko) 2017-11-29
KR102502087B1 true KR102502087B1 (ko) 2023-02-20

Family

ID=56977798

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020177030104A Active KR102502087B1 (ko) 2015-03-25 2016-03-25 혈액 샘플 내의 순환 종양 세포의 디지털 분석

Country Status (10)

Country Link
US (3) US20180057889A1 (enExample)
EP (1) EP3274476B1 (enExample)
JP (2) JP7144934B2 (enExample)
KR (1) KR102502087B1 (enExample)
CN (1) CN107614698A (enExample)
AU (2) AU2016238253B2 (enExample)
CA (1) CA2980562A1 (enExample)
ES (1) ES2954456T3 (enExample)
IL (1) IL254639B (enExample)
WO (1) WO2016154600A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2809813B1 (en) 2012-02-03 2018-08-08 California Institute of Technology Signal encoding and decoding in multiplexed biochemical assays
ES2954456T3 (es) 2015-03-25 2023-11-22 Massachusetts Gen Hospital Análisis digital de células tumorales circulantes en muestras de sangre
EP3532642B1 (en) 2016-10-27 2021-12-08 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers
US20180252722A1 (en) * 2017-03-05 2018-09-06 Yan Wang PCR-based Method for Counting Circulating Tumor Cells
EP3707236A1 (en) * 2017-11-09 2020-09-16 Biomillenia SAS Microbial selection system
US20200399681A1 (en) * 2018-02-23 2020-12-24 Cornell University Assay for detection of androgen receptor variants
CN108535145A (zh) * 2018-03-09 2018-09-14 深圳市瑞图生物技术有限公司 快速检测外周血液中网织红细胞数量的方法及装置
WO2019204357A1 (en) 2018-04-17 2019-10-24 ChromaCode, Inc. Methods and systems for multiplex analysis
CN110456034B (zh) * 2018-05-07 2022-07-22 上海市第十人民医院 一种循环肿瘤细胞的检测方法
US20210172950A1 (en) 2018-06-29 2021-06-10 The General Hospital Corporation Isolating and analyzing rare brain-derived cells and particles
US12203129B2 (en) * 2018-07-03 2025-01-21 ChromaCode, Inc. Formulations and signal encoding and decoding methods for massively multiplexed biochemical assays
CN112996928A (zh) * 2018-09-11 2021-06-18 总医院公司 用于检测肝脏疾病的方法
KR102380529B1 (ko) 2020-04-29 2022-03-31 인제대학교 산학협력단 전이성 전립선 암의 진단 및 예후 예측을 위한 혈중종양세포 기반 바이오 마커 조성물
CN112662774A (zh) * 2021-01-12 2021-04-16 南方医科大学南方医院 一种肝癌循环肿瘤细胞标志物及其应用
CN114395622A (zh) * 2021-12-13 2022-04-26 深圳先进技术研究院 一种利用数字pcr检测循环肿瘤细胞egfr基因突变的方法及其应用
DE102022211089A1 (de) * 2022-10-19 2024-04-25 Robert Bosch Gesellschaft mit beschränkter Haftung Kombinierte Zellspezifische Markierung und Anreicherung von Biomarkern

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063035A1 (en) * 2011-10-24 2013-05-02 The General Hospital Corporation Biomarkers of cancer

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8535A (en) 1851-11-18 Stove-geate
US889A (en) 1838-08-20 Mode of constructing metal bench-vises
DE29623597U1 (de) 1996-11-08 1999-01-07 Eppendorf - Netheler - Hinz Gmbh, 22339 Hamburg Temperierblock mit Temperiereinrichtungen
US20080050393A1 (en) 1998-12-03 2008-02-28 Tang Y Tom Novel nucleic acids and polypeptides
CA2311201A1 (en) * 1999-08-05 2001-02-05 Genset S.A. Ests and encoded human proteins
US20020136728A1 (en) * 2000-08-03 2002-09-26 King Gordon E Compositions and methods for the therapy and diagnosis of colon cancer
WO2002046467A2 (en) 2000-12-08 2002-06-13 Ipsogen Gene expression profiling of primary breast carcinomas using arrays of candidate genes
BR0209646A (pt) 2001-05-16 2006-10-10 Novartis Ag genes expressos em cáncer de mama como alvos de prognósticos e terapêuticos
US20030073623A1 (en) 2001-07-30 2003-04-17 Drmanac Radoje T. Novel nucleic acid sequences obtained from various cDNA libraries
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20060275794A1 (en) 2005-03-07 2006-12-07 Invitrogen Corporation Collections of matched biological reagents and methods for identifying matched reagents
US20070026417A1 (en) * 2005-07-29 2007-02-01 Martin Fuchs Devices and methods for enrichment and alteration of circulating tumor cells and other particles
US20090118175A1 (en) 2005-05-06 2009-05-07 Macina Roberto A Compositions and Methods for Detection, Prognosis and Treatment of Breast Cancer
WO2007136717A1 (en) * 2006-05-16 2007-11-29 Nugen Technologies, Inc. Nucleic acid separation and purification method based on reversible charge interactions
EP2589668A1 (en) * 2006-06-14 2013-05-08 Verinata Health, Inc Rare cell analysis using sample splitting and DNA tags
WO2009051734A1 (en) * 2007-10-17 2009-04-23 The General Hospital Corporation Microchip-based devices for capturing circulating tumor cells and methods of their use
US9068181B2 (en) 2008-05-23 2015-06-30 The General Hospital Corporation Microfluidic droplet encapsulation
US20120252015A1 (en) * 2011-02-18 2012-10-04 Bio-Rad Laboratories Methods and compositions for detecting genetic material
US9625454B2 (en) * 2009-09-04 2017-04-18 The Research Foundation For The State University Of New York Rapid and continuous analyte processing in droplet microfluidic devices
US20110166030A1 (en) * 2009-09-30 2011-07-07 Yixin Wang Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
WO2011100604A2 (en) 2010-02-12 2011-08-18 Raindance Technologies, Inc. Digital analyte analysis
US20120329061A1 (en) * 2010-03-11 2012-12-27 Board Of Regents, The University Of Texas System Quantitative rt-pcr detection for genes involved in epithelial mesenchymal transition in peripheral blood of cancer patients
AU2015268617A1 (en) 2010-03-31 2016-01-07 Sividon Diagnostics Gmbh Method for breast cancer recurrence prediction under endocrine treatment
JP5940517B2 (ja) 2010-03-31 2016-06-29 ジヴィドン ダイアグノスティックス ゲゼルシャフト ミット ベシュレンクテル ハフツング 内分泌治療下における乳癌再発を予測するための方法
US9650629B2 (en) * 2010-07-07 2017-05-16 Roche Molecular Systems, Inc. Clonal pre-amplification in emulsion
AU2011291599B2 (en) 2010-08-18 2015-09-10 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for disease
AU2012220872A1 (en) 2011-02-22 2013-09-12 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers
WO2012135397A2 (en) 2011-03-29 2012-10-04 Lisanti Michael P Lactate-and ketones-induced gene signatures and use the same for diagnosing disease and predicting clinical outcome
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US9766244B2 (en) 2012-07-02 2017-09-19 The General Hospital Corporation Diagnosis and monitoring treatment of prostate cancer
CN104736725A (zh) * 2012-08-13 2015-06-24 加利福尼亚大学董事会 用于检测生物组分的方法和系统
WO2014043628A1 (en) 2012-09-14 2014-03-20 Memorial Sloan-Kettering Cancer Center Genes associated with dasatinib sensitivity
US9671405B2 (en) 2012-09-19 2017-06-06 Cornell University Identifying taxane sensitivity in prostate cancer patients
WO2014075067A1 (en) 2012-11-12 2014-05-15 Nanostring Technologies, Inc. Methods to predict breast cancer outcome
WO2014165762A1 (en) 2013-04-05 2014-10-09 Raindance Technologies, Inc. Rare cell analysis after negative selection
KR20160058774A (ko) 2013-08-12 2016-05-25 토카이 파마슈티컬, 아이엔씨. 안드로겐-표적 치료제를 이용하는 종양 질환 치료를 위한 바이오마커
US10202577B2 (en) 2013-10-18 2019-02-12 The General Hospital Corporation Microfluidic sorting using high gradient magnetic fields
CA2941161A1 (en) 2014-03-13 2015-09-17 F.Hoffmann-La Roche Ag Methods and compositions for modulating estrogen receptor mutants
MA40271A (fr) 2014-05-21 2017-03-29 Hoffmann La Roche Procédés pour traiter le cancer du sein luminal a pr-positif, avec un inhibiteur de pi3k, pictilisib
JP6782698B2 (ja) 2014-12-12 2020-11-11 セルキュイティー インコーポレイテッド がん患者を診断および処置するためのｅｒｂｂシグナル伝達経路活性の測定方法
CN107250385B (zh) 2015-02-20 2021-03-09 考麦兹股份公司 用于切割天然皮革及类似物的方法
PL3268493T3 (pl) 2015-03-12 2022-05-09 Janssen Pharmaceutica Nv Markery mrna oparte na krwi pełnej do przewidywania nowotworu złośliwego prostaty oraz sposoby ich wykrywania
ES2954456T3 (es) 2015-03-25 2023-11-22 Massachusetts Gen Hospital Análisis digital de células tumorales circulantes en muestras de sangre
EP3532642B1 (en) 2016-10-27 2021-12-08 The General Hospital Corporation Digital analysis of blood samples to determine efficacy of cancer therapies for specific cancers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013063035A1 (en) * 2011-10-24 2013-05-02 The General Hospital Corporation Biomarkers of cancer

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Denis A. Smirnov 등, Cancer Res., 65(12), p.4993-4997, 2005.*
Emre Ozkumur 등, Sci. Transl. Med., 5(170), 179ra47, 2013.*
Shannon L. Stott 등, Sci. Transl. Med., 2(25), 25ra23, 2010.*
Valerie Taly 등, Trends in Molecular Medicine, 18(7), p405-416, 2012.*

Also Published As

Publication number Publication date
EP3274476A1 (en) 2018-01-31
JP7144934B2 (ja) 2022-09-30
ES2954456T3 (es) 2023-11-22
IL254639A0 (en) 2017-11-30
WO2016154600A1 (en) 2016-09-29
CN107614698A (zh) 2018-01-19
CA2980562A1 (en) 2016-09-29
US11898209B2 (en) 2024-02-13
HK1249553A1 (en) 2018-11-02
EP3274476A4 (en) 2018-08-29
IL254639B (en) 2021-10-31
US20240132969A1 (en) 2024-04-25
JP7203128B2 (ja) 2023-01-12
JP2021087428A (ja) 2021-06-10
AU2022231734A1 (en) 2022-11-10
US20180057889A1 (en) 2018-03-01
KR20170131516A (ko) 2017-11-29
AU2016238253B2 (en) 2022-06-16
US20210189501A1 (en) 2021-06-24
EP3274476B1 (en) 2023-06-07
JP2018513679A (ja) 2018-05-31
AU2016238253A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
KR102502087B1 (ko) 혈액 샘플 내의 순환 종양 세포의 디지털 분석
JP7441907B2 (ja) 特定のがんに対するがん療法についてその有効性を判定するための血液サンプルのデジタル分析
JP2009529880A (ja) 原発細胞の増殖
EP3356976A1 (en) Immunorepertoire normality assessment method and its use
US12292443B2 (en) Circulating tumor cell based biomarker composition for diagnosis and prognosis of metastatic prostate cancer
CN111819291A (zh) 用于体液鉴定的方法
CN110747275B (zh) 肿瘤细胞标记分子及其应用
US20230002807A1 (en) Methods and compositions for nucleic acid analysis
HK1249553B (en) Digital analysis of circulating tumor cells in blood samples
Teama et al. Detection of circulating tumor cells by nested RT-PCR targeting EGFR/CEA/CK20mRNAs in colorectal carcinoma patients
Telkoparan Akillilar et al. Role of Circulating Tumor Cells and Cell-Free Tumor Deoxyribonucleic Acid Fragments as Liquid Biopsy Materials in Breast Oncology.
Jepson Single-cell MicroRNA Sequencing of Circulating Tumour Cells: A New Tool for Monitoring Prostate Cancer
Škereňová Individualization of the treatment of prostate cancer patients based on the immunocytochemical detection of circulating tumor cells
BEAVER et al. CIRCULATING CELL-FREE DNA
JP2012095554A (ja) 一本鎖ｃＤＮＡの合成方法、マイクロアレイ用試料の調製方法および核酸の検出方法

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171019

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210323

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20220720

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230126

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20230216

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20230216

End annual number: 3

Start annual number: 1

PG1601 Publication of registration